Bladder Cancer
Show Only Open Trials
1.
A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Dendreon
2.
A Phase 1a/b Non-Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nanosuspension for Injection Administered Intravenously to Patients with Solid Tumors
- Study Status: Open to Enrollment
- Sponsor: Berg Pharma
- Disease Status and/or Stage: Advanced Solid Tumors
3.
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B (CALGB); National Cancer Institute (NCI)
- Disease Status and/or Stage: Advanced Transitional Cell Carcinoma
4.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
